Researcher in Human & Molecular Genetics · Targeted Nanomedicine School of Medicine, Universidad Autónoma de Nuevo León (UANL) — Oncology Service, Hospital Universitario "Dr. José Eleuterio González", Monterrey, México. National Researcher (SNII, Level 1).

I work at the interface of cancer biology, genetics and nanomedicine, building both wet-lab strategies and open, reproducible computational tools.

• HER2+ targeted nanomedicine — aptamer-coated AuNPs / polymeric NPs delivering mRNAs, miRNAs, antimiRs and peptides.
• MYC/MAX oncogenic program — pMyc/pMax peptide constructs (prostate cancer).
• In vitro transcription (IVT) mRNA platform — T7, CleanCap, poly(A).
• Post-GWAS functional annotation — reproducible pipelines (T2D / metabolic loci).
• Breast cancer genetics in Northeastern Mexico — gene–environment interactions; ACMG/CAP variant interpretation.

• StriderWeb — nucleic-acid sequence analysis · DOI:10.5281/zenodo.20725635
• PrimerDesigner — PCR primer design (NN Tm, in-silico PCR, Sanger) · DOI:10.5281/zenodo.20725380
• Gallardo BioTools (collection) · DOI:10.5281/zenodo.20723202 · https://gallardo-lab.github.io/gallardo-biotools/

I offer: IVT-mRNA platform, aptamer/NP design, sequence & primer tools, post-GWAS annotation pipeline, cancer-genetics cohorts. I'm interested in: in vivo models, clinical samples, bioinformatics partnerships, and funding for translational nanomedicine. 📫 hugo.gallardobl@uanl.edu.mx

Lab/org @gallardo-lab · Web biosketch · ORCID 0000-0002-7816-4967 · Google Scholar · ResearchGate · LinkedIn

_{Bibliometrics (approx.): h-index 11 (Scopus) / 10 (WoS) · ~300 citations. Code released under MIT unless noted.}